title: Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil.
abstract: OBJECTIVE
  The purpose of the present trial was to clarify the efficacy of postoperative adjuvant chemotherapy including an oral fluoropyrimidine anticancer drug, the 1-hexylcarbamoyl-5-fluorouracil (HCFU), for the treatment of colon cancer.
  
  
  METHODS
  Patients with clinical stage Dukes' B and C colon cancer, who had been treated surgically, were assigned to a chemotherapy group treated with mitomycin C, 5-fluorouracil (5-FU), and HCFU and to a control group that received no postoperative adjuvant chemotherapy.
  
  
  RESULTS
  Of the 1,001 patients registered for the study, 17 (1.7%) were ineligible. The incidence of toxicity was significantly higher in the chemotherapy group than in the control group. However, there were few severe side effects and no deaths related to the treatment. Overall survival showed no significant difference between the groups. The disease-free survival or the recurrence-free intervals was significantly higher in the chemotherapy group than in the control group. The incidence of hepatic recurrence was significantly (P=0.003) lower in the chemotherapy group than in the control group.
  
  
  CONCLUSIONS
  The results of this study demonstrated the efficacy of adjuvant chemotherapy for colon cancer, i.e., combined chemotherapy that included the 5-FU oral anticancer drug HCFU.
authors.affiliation: Department of Surgery, School of Medicine, Kitasato University, 1-15-1, Kitasato, Sagamihara, Kanagawa, 228-8555, Japan. midoris@med.kitasato-u.ac.jp
authors.forename: Masahiko
authors.initials: M
authors.lastname: Watanabe
authors.forename: Susumu
authors.initials: S
authors.lastname: Kodaira
authors.forename: Takashi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tominaga
authors.forename: Keiichi
authors.initials: K
authors.lastname: Hojo
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Kato
authors.forename: Kazufumi
authors.initials: K
authors.lastname: Kunitomo
authors.forename: Hiroharu
authors.initials: H
authors.lastname: Isomoto
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ohashi
authors.forename: Masayuki
authors.initials: M
authors.lastname: Yasutomi
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects; D009367:Neoplasm Staging; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D016685:Mitomycin; C017367:carmofur; D005472:Fluorouracil